

RECEIVED

APR 11 2003

TECH CENTER 1600/2800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 037003-0280728
Client Ref. No. 2000-30-0513A

In re Application of: Michael Reff

Serial No: 09/982,849

Filed: October 22, 2001

Title: VARIANT IgG3 RITUXAN AND
THERAPEUTIC USES THEREOF

) Examiner: To be assigned
)
)

) Art Unit: 1644
)

) Certificate of Mailing Under §1.10
)

) I, Patricia Munoz, hereby certify that this paper
) or fee is being deposited with the United States
) Postal Service as Express Mail Post Office to
) Addressee service, Express Mailing Label No.
) EV 159 088 420 US, under 37 C.F.R. § 1.10 on
) the date indicated below and is addressed to the
) Hon. Commissioner of Patents and Trademarks,
) Washington D.C. 20231 on this date.

) Date: April 8, 2003

) By: Patricia Munoz
Patricia Munoz

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants request that the information on the attached Form PTO-1449 be considered by the Office during the pendency of the above-entitled application, pursuant to 37 C.F.R. 1.97. In accordance with 37 C.F.R. 1.97(h), the filing of the Information Disclosure Statement shall not constitute an admission that any information cited therein is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b). In the interest of full and complete disclosure to the Office, some or all of the art cited herein may not be considered by Applicant(s) or the Undersigned to be material under the standards of materiality defined in C.F.R. 1.56(b), enacted

March 16, 1992, and may merely be technical background which may be of interest to the Examiner.

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Since no Office Action on the merits has issued, Applicants believe that no fee is due in connection with the filing of this Information Disclosure Statement. However, please charge any fees that may be necessary to Deposit Account No. 03-3975, Order No. 037003-0280728.


Respectfully submitted,

Date: Apr 18, 2003



Suzanne L. Biggs
Registration No. 30,158

PILLSBURY WINTHROP LLP
11682 El Camino Real, Suite 200
San Diego, CA 92130
Telephone: (858) 509-4022
Fax Line: (858) 509-4010



Atty.
Dkt. No.

M#

Client Ref.

0280728

200039053A

RECEIVED

Applicant: Mitchell Reff

APR 11 2003

Appln. No.: 09/982,846

TECH CENTER 1600/2900

Filing Date: October 22, 2001

Examiner: TBA

Group Art Unit: 1644

Date: April 8, 2003

Page

1

of

2

U.S. PATENT DOCUMENTS


Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Availabl	
						Enclosed	No	Enclos	No
	BR	WO 99/54342	10/1999	PCT	Umana et al.				
	CR	WO 98/37099	08/1998	PCT	Reff et al.				
	DR	WO 00/27433	05/2000	PCT	Grillo-Lopez et al.				
	ER								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

FR	Grillo-Lopez et al., "Rituximab: The First Monoclonal Antibody Approved for the Treatment of Lymphoma", Current Pharmaceutical Biotechnology 1:1-9 (2000)			
GR	Jiang et al., "Enhanced Effector Functions of Dimeric Forms of IDEC-C2B8 (rituximab)", Blood, 92:86A, Abstract # 376 (1999)			
HR	Czuczman et al., "Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy", Journal of Clinical Oncology, 17:268-276 (1999)			
IR	Davis et al., "Combination Immunotherapy of Low Grade or Follicular (LG/F) Non-Hadgkins Lymphoma (NHL) with Rituximab and Alpha Interferon: Interim Analysis", Proc Annu Meet Am Soc Clin Oncol, 17:A39 (1998)			
JR	Flinn et al., "In Vivo Purging and Adjuvant Immunotherapy with Rituximab During PBSC Transplant for NHL", Blood 92:648A, Abstract # 2673 (1998)			
KR	Davis et al., "Rituximab: Phase II (PII) Retreatment (ReRx) Study in Patients (PTS) with Low-Grade or Follicular (LG/F) NHL", Blood 92:414A, Abstract #1710 (1998)			
LR	Van der Kolk et al., "Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) Plus G-CSF in Relapsed B-Cell Lymphoma: A Phase I/II Clinical Trial", British Journal of Heamatology 102:243, Abstract #4037 (1998)			
MR	Press et al., "A Phase I/II Trial of High Dose Iodine-131-Anti-B1 (Anti-CD20) Monoclonal Antibody, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation for Patients with Relapsed B-Cell Lymphomas", Proc Annu Meet Am Soc Clin Oncol, 17:A509 (1998)			
NR	Davis et al., "Retreatments with Rituxan (Rituximab, IDEC-C2B8) have significant efficacy, do not cause hama, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL)", Blood, 90:509a (1997)			
OR	Wahl et al., "Successful Re-Treatment of Non-Hodgkin's Lymphoma (NHL) with Iodine-131 Anti-B1 Antibody", Proc Annu Meet Soc Clin Oncol, 17:A156 (1998)			



PR	Press, Oliver W., "Prospects for the Management of Non-Hodgkin's Lymphomas with Monoclonal Antibodies and Immunoconjugates", The Cancer Journal from Scientific American, 4:S19-S26 (1988)			
QR	Kuzel et al., "A Phase I Escalating-Dose Safety, Dosimetry and Efficacy Study of Radiolabeled Monoclonal Antibody LYM-1", Cancer Biotherapy, 8:3-16 (1993)			
RR	Knox et al., "Yttrium-90-labeled Anti-CD20 Monoclonal Antibody Therapy of Relapsed B-Cell Lymphoma", Clinical Cancer Research, 3:457-470 (1996)			
SR	McLaughlin et al., "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program", Journal of Clinical Oncology, 16:2825-2833 (1998)			
TR	Maloney et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma", Journal of Clinical Oncology, 15:3266-3274 (1997)			
UR	Van der Kolk et al., "Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) Plus G-CSF in Relapsed B-Cell Lymphoma: A Phase I/II Clinical Trial", Blood, 92:241B (1998)			

RECEIVED

APR 11 2003

TECH CENTER 1800/2900

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.